Search Results - Sander Croes

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Vancomycin dosing in neutropenic patients. by Michiel B Haeseker, Sander Croes, Cees Neef, Cathrien A Bruggeman, Leo M L Stolk, Annelies Verbon

    Published in PLoS ONE (2014-01-01)
    Get full text
    Article


  2. 2

    Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer by Judith Gulikers, Jeroen Bruinsma, Janna Schoenmaekers, Safiye Dursun, Vivianne Tjan-Heijnen, Robin van Geel, Sander Croes, Lizza Hendriks

    Published in Therapeutic Advances in Medical Oncology (2024-12-01)
    Get full text
    Article


  3. 3

    Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerResearch in context by G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen

    Published in EClinicalMedicine (2023-05-01)
    Get full text
    Article


  4. 4

    Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, mul... by Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken

    Published in Frontiers in Oncology (2023-03-01)
    Get full text
    Article


  5. 5

    Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC by Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD

    Published in JTO Clinical and Research Reports (2024-04-01)
    Get full text
    Article


Search Tools: